UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 4, 2004
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
|
Massachusetts |
|
0-17999 |
|
04-2726691 |
|
(State or other |
|
(Commission |
|
(IRS Employer |
|
|
||||
|
128 Sidney Street, Cambridge, MA 02139 |
||||
|
(Address of principal executive offices) (Zip Code) |
||||
|
|
||||
|
Registrant’s telephone number, including area code: (617) 995-2500 |
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION
On November 4, 2004, ImmunoGen, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2004. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
The information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits:
99.1 Press Release of ImmunoGen, Inc. dated November 4, 2004
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ImmunoGen, Inc. |
|
|
|
|
(Registrant) |
||
|
|
|
||
|
Date: November 4, 2004 |
/s/ Christopher U. Missling |
|
|
|
|
|
||
|
|
Christopher U. Missling |
||
|
|
Chief Financial Officer and Vice President, |
||
|
|
Finance and Treasurer |
||
3
EXHIBIT INDEX
|
Exhibit No. |
|
Exhibit |
|
|
|
|
|
99.1 |
|
Press Release of ImmunoGen, Inc. dated November 4, 2004 |
4